Survey of the Jan Pariyojana Scheme in India and its impact on citizens during the previous decade
Abstract
It is a well-known fact that Branded medicines are sold at significantly higher prices in India. Making affordable, high-quality pharmaceuticals available on the market will help everyone, but mainly the underprivileged and destitute given the country's pervasive poverty. The Indian government has always been quite concerned about this. The Ministry of Chemicals and Fertilizers' Department of Pharmaceutical has periodically implemented a number of regulatory and financial initiatives to achieve this goal.
The "Pradhan Mantri Bhartiya Jan Aushadhi Pariyojana" is a wonderful project started by the Indian government back in 2008 for the worthy purpose of providing high quality medications at accessible prices to all.
The Pariyojana involved selling inexpensive generic medications through upscale retailers called "Pradhan Mantri Bhartiya Jan Oshadhi Kendra" in different regions of the nation. On November 25, 2008, the first "Pradhan Mantri Bhartiya Jan Oshadhi Kendra" in Punjab's Amritsar city was inaugurated.
At first, it was planned that the "Pradhan Mantri Bhartiya Jan Oshadhi Pariyojana" would be implemented during the 11th Five-Year Plan period, beginning in 2008-2009, with the goal of establishing at least each Pradhan Mantri Bhartiya Jan Oshadhi Kendra in each of the firm's 630 regions, and then expanding to sub divisional levels as well as major town and village centers by 2012.
After garnering early support, the concept was planned to be self-sustaining and not rely on government subsidies or assistance. It was to be run on the basis of "No Profit, No Loss."
Downloads
References
2. N. M, K. NG, P. D, N. SG, Nagaral J v., V. RB, et al. Analysis of cost between branded medicines and generic medicines in a tertiary care hospital. Int J Basic ClinPharmacol. 2019 Apr 23;8(5):1074.
3. Jayaraman K. Troubles beset “Jan Aushadhi” plan to broaden access to generics. Nat Med. 2010;16:350.
4. Chaudhary RK, Philip MJ, Santhosh A, Karoli SS, Bhandari R, Ganachari MS. Health economics and effectiveness analysis of generic anti-diabetic medication from jan aushadhi: An ambispective study in community pharmacy. Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102303.
doi: 10.1016/j.dsx.2021.102303
5. Milton Solomon C, Sundar C. Impact of Brand Awareness and Customer Satisfaction Towards Services of Jan Aushadhi Medical stores. International Journal of Recent Technology and Engineering. 2019 Aug 27;8(2S4):546-51.
6. Uvais NA. A cost analysis of the psychotropic medicines sold in the janaushadhi generic drug stores in India. Asian J Psychiatr. 2018 Mar;33:40-1
7. Mukherjee K. A Cost Analysis of the Jan Aushadhi Scheme in India.Int J Health Policy Manag. 2017 Jan 17;6(5):253-6.
8. Satheesh G, Unnikrishnan MK, Sharma A. Challenges constraining availability and affordability of insulin in Bengaluru region (Karnataka, India): evidence from a mixed-methods study. J Pharm Policy Pract 2019;12:31.
doi: 10.1186/s40545-019-0190-1
9. Ahmad A, Patel I, Sanyal S, Balkrishnan R, Mohanta GP. Availability, cost and affordability of antimalarial medicines in India! International Journal of Pharmaceutical and Clinical Research. 2014; 6(1):7-12
10. Shaik R, Muragundi PM. Evaluation of price disparity among generic medicines in india. Asian Journal of Pharmaceutical and Clinical Research. 2018;11(12):466-468
11. Ray A, Najmi A, Khandelwal G, Sadasivam B. A Cost Variation Analysis of Drugs Available in the Indian Market for the Management of Thromboembolic Disorders. Cureus. 2020 May 5;12(5):e7964. doi: 10.7759/cureus.7964.
12. Chavda N, Patel NM, Tandel K, Dhanani J v., Solanky P. Study of medical student’s perspectives about prescribing generic medicine at tertiary care teaching hospital. Natl J Physiol Pharm Pharmacol. 2017;7(10):1.
13. C. R., Manasa; L., Kalpana; R. M., Veena. Generic drugs: a study on awareness among medical students and interns. Int J Basic ClinPharmacol. 2020;9(12):1877-1882
14. Singh, B., Nanda, A., Budhwar, V. and Marwaha, R. 2016. A comparative evaluation of the quality and price of generic medicine with their branded counterparts. PharmaTutor. Oct. 2016;4(10):43-49
15. Kashyap A, Balaji MN, Chhabra M, Rashid M, Muragundi PM. Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India. Expert Rev Pharmacoecon Outcomes Res. 2020 Aug;20(4):355-361.
doi: 10.1080/14737167.2019.1637735..
16. Thawani V, Mani A, Upmanyu N. Why the Jan Aushadhi Scheme Has Lost Its Steam in India? J Pharmacol Pharmacother. 2017 Jul-Sep;8(3):134-136.
doi: 10.4103/jpp.JPP_38_17.
17. G. Rajini, G. Madhumita. Vital Factors Influencing Purchase of Over the Counter (Otc) Medicines: Brand Experiences of Gen X and new age Indian women. Research J. Pharm. and Tech. 2019; 12(6): 2682-2686. doi: 10.5958/0974-360X.2019.00448.7.
18. Janodia M. Differences in Price of Medicines Available from Pharmaceutical Companies and “Jan Aushadhi” Stores. Value in Health. 2015;18(7).
19. Ahire K, Shukla M, Gattani M, Singh V, Singh M. A survey based study in current scenario of generic and branded medicines. Int J Pharm Pharm Sci. 2013;5(3):705-711
20. Soni MS, Pawar AP, Bothiraja C, Gaikwad VL. Comparative pharmaceutical evaluation of variable retail priced medicines containing biopharmaceutical classification system class-II or class-IV drugs. Indian Drugs. 2021;58(4):63-73.
21. Charan J, Saxena D, Chaudhri M, Dutta S, Kaur RJ, Bhardwaj P. Opinion of primary care physicians regarding prescription of generic drugs: A Cross-sectional study. J Family Med Prim Care. 2021 Mar;10(3):1390-1398.
doi: 10.4103/jfmpc.jfmpc_2157_20. Epub 2021 Apr 8.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
